The treatment of recurrent @entity463 ( @entity463 ) remains challenging notwithstanding the recent approval of bevacizumab for this indication. @entity11441 has a bifunctional mechanism of action including alkylation, penetrates the CNS and does not show cross resistance to other alkylator chemotherapies. In a single institution phase 2 trial, @entity1 with recurrent @entity463 were treated with @entity11441 (100 mg/m(2)/day administered intravenously for two consecutive days every 4 weeks). The primary study endpoint was 6-month progression free survival (PFS-6). An interim analysis for futility was conducted according to a Simon two-stage minimax design. Complete blood counts were obtained bimonthly, clinical evaluations and brain imaging every month for the first cycle and bimonthly thereafter. Treatment responses were based upon MacDonald criteria. Sixteen @entity1 were enrolled (nine @entity1 ; seven @entity1 ), with a median age of 53 years (range 36-68) and a median Karnofsky performance status of 90 (range 70-100). Nine @entity1 were treated at first relapse and seven at second relapse (five @entity1 were @entity177 ). A total of 25 cycles of @entity11441 were administered with a median of 1 (range 1-6). @entity11441 -related @entity137 was seen in eight @entity1 ; @entity2905 in seven (5 grade 3; 2 Grade 4), @entity882 in two (1 Grade 3; 1 Grade 4), and @entity1398 in one (1 Grade 3). Fourteen @entity1 have died due to disease progression, two @entity1 are alive and on alternative therapies. Only one @entity1 was progression-free at 6 months, triggering the stopping rule for futility. @entity11441 was reasonably well tolerated but failed to meet the study criteria for activity in adults with recurrent @entity463 .

Salvage therapy with single agent XXXX for recurrent @entity463 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity11441 :: ('MESH:C001758', 'Chemical') :: ['Bendamustine', 'bendamustine'] @entity2905 :: ('MESH:D008231', 'Disease') :: ['lymphopenia'] @entity177 :: ('MESH:D051437', 'Disease') :: ['bevacizumab failures'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity463 :: ('MESH:D005909', 'Disease') :: ['GBM', 'glioblastoma']
@entity11441 :: (MESH:C001758,Chemical) :: ['bendamustine']
